Canavan disease: A white matter disorder

Mental Retardation and Developmental Disabilities Research Reviews

Volumn 12, Issue 2, 2006, Pages 157-165

  Kumar, Shalini ^a   Mattan, Natalia S ^a   De Vellis, Jean ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Demyelination; Hypomyelination; NAA; Oligodendrocyte

Indexed keywords

ACETIC ACID; ASPARTOACYLASE; COMPLEMENTARY DNA; LITHIUM; MANNITOL; MYELIN; N ACETYLASPARTIC ACID; PARVOVIRUS VECTOR;

ASPA GENE; BRAIN DEVELOPMENT; BRAIN DISEASE; BRAIN REGION; CANAVAN DISEASE; CELL FUNCTION; CELL INTERACTION; CELL LINEAGE; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DISEASE MODEL; DRUG TARGETING; GENE; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENETIC COUNSELING; HUMAN; LEUKODYSTROPHY; MOTOR PERFORMANCE; MOUSE STRAIN; MYELIN DEFICIENCY; MYELINATION; NERVE CELL; NERVE CELL DEGENERATION; NERVE FIBER DEGENERATION; NONHUMAN; OLIGODENDROGLIA; PATHOPHYSIOLOGY; PELIZAEUS MERZBACHER DISEASE; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS TYPING; WHITE MATTER; WHITE MATTER DISORDER;

ASPARTIC ACID; BIOLOGICAL MARKERS; BRAIN; CANAVAN DISEASE; DIAGNOSIS, DIFFERENTIAL; GENETIC COUNSELING; GLUTAMIC ACID; HOMEOSTASIS; HUMANS; INFANT; MAGNETIC RESONANCE IMAGING; MYELIN SHEATH; NEUROGLIA; NEURONS; OLIGODENDROGLIA;

EID: 33745685978     PISSN: 10804013     EISSN: 10982779     Source Type: Journal    
DOI: 10.1002/mrdd.20108     Document Type: Review

References (133)

1. Adachi M, Schneck L, Cara J, et al. 1973. Spongy degeneration of the CNS (van Bogaert and Bertrand type; Canavan's disease). A review. Hum Pathol 4:331-347.
2. Adachi M, Volk BW. 1968. Protracted form of spongy degeneration of the CNS (van Bogaert and Bertrand type). Neurology 18:1084-1092.
3. Adachi M, Wallace BJ, Schneck L, et al. 1966. Fine structure of spongy degeneration of the CNS (van Bogaert and Bertrand type). J Neuropathol Exp Neurol 25:598-616.
4. Adachi M, Wallace BJ, Volk BW. 1967. Ultramicroscopic and histochemical studies of spongy degeneration (van Bogaert and Bertrand type). J Neuropathol Exp Neurol 26:164, 165.
5. Aicardi J. 1993. The inherited leukodystrophies: A clinical overview. J Inherit Metab Dis 16: 733-743.
6. Aronica E, van Vliet EA, Mayboroda OA, et al. 2000. Upregulation of metabotropic glutamate receptor subtype mGluR3 and mGluR5 in reactive astrocytes in a rat model of mesial temporal lobe epilepsy. Eur J Neurosci 12: 2333-2344.
7. Aston C, Jiang L, Sokolov BP. 2004. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J Neurosci Res 77:858-866.
8. Banker BQ, Robertson JT, Victor M. 1964. Spongy degeneration of the CNS in infancy. Neurology 14:981-1001.
9. Banker BQ, Victor M. 1979. Spongy Degeneration of Infancy. New York: Raven.
10. Barash V, Flhor D, Morag B, et al. 1991. A radiometric assay for aspartoacylase activity in human fibroblasts: Application for the diagnosis of Canavan's disease. Clin Chim Acta 201: 175-181.
11. Barkhof F, van Walderveen M. 1999. Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance. Philos Trans R Soc Lond B Biol Sci 354:1675-1686.
12. Baslow MH. 1998. Function of the N-acetyl-L-histidine system in the vertebrate eye. Evidence in support of a role as a molecular water pump. J Mol Neurosci 10:193-208.
13. Baslow MH. 1999. Molecular water pumps and the aetiology of Canavan disease: A case of the sorcerer's apprentice. J Inherit Metab Dis 22: 99-101.
14. Baslow MH. 2000. Functions of N-acetyl-L-aspartate and N-acetyl-L-aspartylglutamate in the vertebrate brain: Role in glial cell-specific signaling. J Neurochem 75:453-459.
15. Baslow MH. 2002. Evidence supporting a role for N-acetyl-L-aspartate as a molecular water pump in myelinated neurons in the CNS. An analytical review. Neurochem Int 40:295-300.
16. Belachew S, Gallo V. 2004. Synaptic and extrasynaptic neurotransmitter receptors in glial precursors' quest for identity. Glia 48:185-196.
17. Berger UV, Luthi-Carter R, Passani LA, et al. 1999. Glutamate carboxypeptidase II is expressed by astrocytes in the adult rat nervous system. J Comp Neurol 415:52-64.
18. Bhakoo KK, Pearce D. 2000. In vitro expression of N-acetyl aspartate by oligodendrocytes: Implications for proton magnetic resonance spectroscopy signal in vivo. J Neurochem 74: 254-262.
19. Bhakoo KK, Williams SR, Florian CL, et al. 1996. Immortalization and transformation are associated with specific alterations in choline metabolism. Cancer Res 56:4630-4635.
20. Block W, Jessen F, Traber F, et al. 2002. Regional N-acetylaspartate reduction in the hippocampus detected with fast proton magnetic resonance spectroscopic imaging in patients with Alzheimer disease. Arch Neurol 59:828-834.
21. Bluml S. 1999. In vivo quantitation of cerebral metabolite concentrations using natural abundance 13C MRS at 1.5 T. J Magn Reson 136:219-225.
22. Bluml S, Moreno A, Hwang JH, et al. 2001. 1-(13)C glucose magnetic resonance spectroscopy of pediatric and adult brain disorders. NMR Biomed 14:19-32.
23. Boison D, Stoffel W. 1989. Myelin-deficient rat: A point mutation in exon III (A-C, Thr75-Pro) of the myelin proteolipid protein causes dysmyelination and oligodendrocyte death. EMBO J 8:3295-3302.
24. Breitbach-Faller N, Schrader K, Rating D, et al. 2003. Ultrasound findings in follow-up investigations in a case of aspartoacylase deficiency (Canavan disease). Neuropediatrics 34:96-99.
25. Brismar J, Brismar G, Gascon G, et al. 1990. Canavan disease: CT and MR imaging of the brain. AJNR Am J Neuroradiol 11:805-810.
26. Buchanan DS, Davis RL. 1965. Spongy degeneration of the nervous system. A report of four cases with a review of the literature. Neurology 15:207-222.
27. Buhrer C, Bassir C, von Moers A, et al. 1993. Cranial ultrasound findings in aspartoacylase deficiency (Canavan disease). Pediatr Radiol 23:395-397.
28. Burlina AP, Ferrari V, Burlina AB, et al. 2006. N-acetylaspartylglutamate (NAAG) in Pelizaeus-Merzabacher Disease. New York: Springer.
29. Canavan M. 1931. Schilder's encephalitis periaxialis diffusa. Report of a case in a child aged sixteen and one-half months. Arch Neurol Psychiatry 25:299-308.
30. Chakraborty G, Mekala P, Yahya D, et al. 2001. Intraneuronal N-acetylaspartate supplies acetyl groups for myelin lipid synthesis: Evidence for myelin-associated aspartoacylase. J Neurochem 78:736-745.
31. Choi DW. 1994. Glutamate receptors and the induction of excitotoxic neuronal death. Prog Brain Res 100:47-51.
32. Chong ZZ, Kang JQ, Maiese K. 2003. Metabotropic glutamate receptors promote neuronal and vascular plasticity through novel intracellular pathways. Histol Histopathol 18:173-189.
33. Ciccarelli R, Di Iorio P, Bruno V, et al. 1999. Activation of A(1) adenosine or mGlu3 metabotropic glutamate receptors enhances the release of nerve growth factor and S-100β protein from cultured astrocytes. Glia 27:275-281.
34. Csiza CK, de Lahunta A. 1979. Myelin deficiency (md): A neurologic mutant in the Wistar rat. Am J Pathol 95:215-223.
35. Davidson BL, Stein CS, Heth JA, et al. 2000. Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian CNS. Proc Natl Acad Sci USA 97:3428-3432.
36. De Stefano N, Iannucci G, Sormani MP, et al. 2002. MR correlates of cerebral atrophy in patients with multiple sclerosis. J Neurol 249: 1072-1077.
37. Degaonkar MN, Khubchandhani M, Dhawan JK, et al. 2002. Sequential proton MRS study of brain metabolite changes monitored during a complete pathological cycle of demyelination and remyelination in a lysophosphatidyl choline (LPC)-induced experimental demyelinating lesion model. NMR Biomed 15:293-300.
38. Deng W, Poretz RD. 2003. Oligodendroglia in developmental neurotoxicity. Neurotoxicology 24:161-178.
39. Dentinger MP, Barron KD, Csiza CK. 1982. Ultrastructure of the CNS in a myelin deficient rat. J Neurocytol 11:671-691.
40. Dentinger MP, Barron KD, Csiza CK. 1985. Glial and axonal development in optic nerve of myelin deficient rat mutant. Brain Res 344: 255-266.
41. Divry P, Mathieu M. 1989. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am J Med Genet 32(4):550, 551.
42. Divry P, Vianey-Liaud C, Gay C, et al. 1988. N-acetylaspartic aciduria: Report of three new cases in children with a neurological syndrome associating macrocephaly and leukodystrophy. J Inherit Metab Dis 11:307, 308.
43. Echenne B, Divry P, Vianey-Liaud C. 1989. Spongy degeneration of the neuraxis (Canavan-van Bogaert disease) and N-acetylaspartic aciduria. Neuropediatrics 20:79-81.
44. Elpeleg ON, Shaag A. 1999. The spectrum of mutations of the aspartoacylase gene in Canavan disease in non-Jewish patients. J Inherit Metab Dis 22:531-534.
45. Elpeleg ON, Shaag A, Anikster Y, et al. 1994. Prenatal detection of Canavan disease (aspartoacylase deficiency) by DNA analysis. J Inherit Metab Dis 17:664-666.
46. Engelbrecht V, Rassek M, Gartner J, et al. 1995. Magnetic resonance tomography and localized proton spectroscopy in 2 siblings with Canavan's disease. Rofo 163:238-244.
47. Engelhardt E, Moreira DM, Laks J, et al. 2001. Alzheimer's disease and magnetic resonance spectroscopy of the hippocampus. Arq Neuropsiquiatr 59:865-870.
48. Espinosa de los Monteros A, Zhang M, Gordon MN, et al. 1990. The myelin-deficient rat mutant: Partial recovery of oligodendrocyte maturation in vitro. Dev Neurosci 12:326-339.
49. Espinosa de los Monteras A, Zhang MS, Gordon M, et al. 1992. Transplantation of cultured premyelinating oligodendrocytes into normal and myelin-deficient rat brain. Dev Neurosci 14:98-104.
50. Firbank MJ, Harrison RM, O'Brien JT. 2002. A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease. Dement Geriatr Cogn Disord 14:64-76.
51. Gambetti P, Mellman WJ, Gonatas NK. 1969. Familial spongy degeneration of the CNS (Van Bogaert-Bertrand disease). An ultrastructural study. Acta Neuropathol (Berl) 12:103-115.
52. Ghadge GD, Slusher BS, Bodner A, et al. 2003. Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc Natl Acad Sci USA 100:9554-9559.
53. Globus J, Strauss I. 1928. Progressive degenerative subcortical encephalopathy (Schilder's disease). Arch Neurol Psychiatry 20:1190-1228.
54. Gordon MN, Kumar S, Espinosa de los Monteros A, et al. 1992. Ontogeny of glycerol phosphate dehydrogenase-positive oligodendrocytes in rat brain. Impaired differentiation of oligodendrocytes in the myelin deficient mutant rat. Int J Dev Neurosci 10:243-253.
55. Govindaraju V, Young K, Maudsley AA. 2000. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed 13:129-153.
56. Grodd W, Krageloh-Mann I, Klose U, et al. 1991. Metabolic and destructive brain disorders in children: Findings with localized proton MR spectroscopy. Radiology 181:173-181.
57. Hagenfeldt L, Bollgren I, Venizelos N. 1987. N-acetylaspartic aciduria due to aspartoacylase deficiency-A new aetiology of childhood leukodystrophy. J Inherit Metab Dis 10:135-141.
58. Haselgrove J, Moore J, Wang Z, et al. 2000. A method for fast multislice T1 measurement: Feasibility studies on phantoms, young children, and children with Canavan's disease. J Magn Reson Imaging 11:360-367.
59. Inoue Y, Kuhara T. 2004. Rapid and sensitive screening for and chemical diagnosis of Canavan disease by gas chromatography-mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 806:33-39.
60. Jakobs C, ten Brink HJ, Divry P, et al. 1992. Prenatal diagnosis of Canavan disease. Eur Disabil Rehabil 151:620.
61. Jakobs C, ten Brink HJ, Langelaar SA, et al. 1991. Stable isotope dilution analysis of N-acetylaspartic acid in CSF, blood, urine and amniotic fluid: Accurate postnatal diagnosis and the potential for prenatal diagnosis of Canavan disease. J Inherit Metab Dis 14:653-660.
62. Janson CG, Assadi M, Francis J, et al. 2005. Lithium citrate for Canavan disease. Pediatr Neurol 33:235-243.
63. Janson CG, McPhee SW, Leone P, et al. 2001. Viral-based gene transfer to the mammalian CNS for functional genomic studies. Trends Neurosci 24:706-712.
64. Jessen F, Traeber F, Freymann N, et al. 2005. A comparative study of the different N-acetylaspartate measures of the medial temporal lobe in Alzheimer's disease. Dement Geriatr Cogn Disord 20:178-183.
65. Kapeller P, Brex PA, Chard D, et al. 2002. Quantitative 1H MRS imaging 14 years after presenting with a clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 8:207-210.
66. Kapeller P, McLean MA, Griffin CM, et al. 2001. Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing-remitting multiple sclerosis: A quantitative MR spectroscopic imaging study. J Neurol 248: 131-138.
67. Kapeller P, Ropele S, Enzinger C, et al. 2005. Discrimination of white matter lesions and multiple sclerosis plaques by short echo quantitative 1H-magnetic resonance spectroscopy. J Neurol 252:1229-1234.
68. Kato T, Nishina M, Matsushita K, et al. 1997. Neuronal maturation and N-acetyl-L-aspartic acid development in human fetal and child brains. Brain Dev 19:131-133.
69. Kaul R, Casanova J, Johnson AB, et al. 1991. Purification, characterization, and localization of aspartoacylase from bovine brain. J Neurochem 56:129-135.
70. Kaul R, Gao GP, Aloya M, et al. 1994. Canavan disease: Mutations among Jewish and non-Jewish patients. Am J Hum Genet 55:34-41.
71. Kaul R, Gao GP, Balamurugan K, et al. 1993. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease. Nat Genet 5:118-123.
72. Kelley RI. 1993. Prenatal detection of Canavan disease by measurement of N-acetyl-L-aspartate in amniotic fluid. J Inherit Metab Dis 16:918, 919.
73. Kelley RI, Stamas JN. 1992. Quantification of N-acetyl-L-aspartic acid in urine by isotope dilution gas chromatography-mass spectrometry. J Inherit Metab Dis 15:97-104.
74. Klugmann M, Leichtlein CB, Symes CW, Serikawa T, Young D, During MJ. 2005. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease. Mol Ther 11:745-753.
75. Kronn D, Oddoux C, Phillips J, et al. 1995. Prevalence of Canavan disease heterozygotes in the New York metropolitan Ashkenazi Jewish population. Am J Hum Genet 57:1250-1252.
76. Kumar S, Gordon MN, Espinosa de los Monteros MA, et al. 1988. Developmental expression of neural cell type-specific mRNA markers in the myelin-deficient mutant rat brain: Inhibition of oligodendrocyte differentiation. J Neurosci Res 21:268-274.
77. Kumar S, Macklin WB, Gordon MN, et al. 1990. Transcriptional regulation studies of myelin-associated genes in myelin-deficient mutant rats. Dev Neurosci 12:316-325.
78. Kumar S, Somyalakshmi R, Daniels SL, et al. 2006. Does ASPA Gene Mutation in Canavan Disease Alter Oligodendrocyte Development? A Tissue Culture Study of ASPA KO Mice Brain. New York: Springer.
79. Kvittingen EA, Guldal G, Bursting S, et al. 1986. N-acetylaspartic aciduria in a child with a progressive cerebral atrophy. Clin Chim Acta 158:217-227.
80. Leone P, Janson CG, Bilaniuk L, et al. 2000. Aspartoacylase gene transfer to the mammalian CNS with therapeutic implications for Canavan disease. Ann Neurol 48:27-38.
81. Liu XB, Munoz A, Jones EG. 1998. Changes in subcellular localization of metabotropic glutamate receptor subtypes during postnatal development of mouse thalamus. J Comp Neurol 395:450-465.
82. Lu ZH, Chakraborty G, Ledeen RW, et al. 2004. N-acetylaspartate synthase is bimodally expressed in microsomes and mitochondria of brain. Brain Res Mol Brain Res 122:71-78.
83. Madhavarao CN, Chinopoulos C, Chandrasekaran K, et al. 2003. Characterization of the N-acetylaspartate biosynthetic enzyme from rat brain. J Neurochem 86:824-835.
84. Madhavarao CN, Moffett JR, Moore RA, et al. 2004. Immunohistochemical localization of aspartoacylase in the rat CNS. J Comp Neurol 472:318-329.
85. Mastakov MY, Baer K, Kotin RM, et al. 2002. Recombinant adeno-associated virus serotypes 2- and 5-mediated gene transfer in the mammalian brain: Quantitative analysis of heparin co-infusion. Mol Ther 5:371-380.
86. Matalon R, Kaul R, Casanova J, et al. 1989. SSIEM Award. Aspartoacylase deficiency: The enzyme defect in Canavan disease. J Inherit Metab Dis 12 (Suppl 2):329-331.
87. Matalon R, Michals K, Kaul R. 1995. Canavan disease: From spongy degeneration to molecular analysis. Disabil Rehabil 127:511-517.
88. Matalon R, Michals K, Sebesta D, et al. 1988. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am J Med Genet 29:463-471.
89. Matalon R, Rady PL, Platt KA, et al. 2000. Knockout mouse for Canavan disease: A model for gene transfer to the CNS. J Gene Med 2:165-175.
90. Matalon R, Surendran S, Rady PL, et al. 2003. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease. Mol Ther 7(5, Part 1):580-587.
91. Matalon RM, Michals-Matalon K. 2000. Spongy degeneration of the brain, Canavan disease: Biochemical and molecular findings. Front Biosci 5:D307-D311.
92. Mathew R, Arun P, Madhavarao CN, et al. 2005. Progress toward acetate supplementation therapy for Canavan disease: Glyceryl triacetate administration increases acetate, but not N-acetylaspartate, levels in brain. J Pharmacol Exp Ther 315:297-303.
93. McPhee SW, Francis J, Janson CG, et al. 2005. Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease. Brain Res Mol Brain Res 135: 112-121.
94. Miller BL. 1991. A review of chemical issues in 1H NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline. NMR Biomed 4:47-52.
95. Miyake M, Kakimoto Y, Sorimachi M. 1981. A gas chromatographic method for the determination of N-acetyl-L-aspartic acid, N-acetyl-α- aspartylglutamic acid and β-citryl-L-glutamic acid and their distributions in the brain and other organs of various species of animals. J Neurochem 36:804-810.
96. Moffett JR, Namboodiri MA. 1995. Differential distribution of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat forebrain. J Neurocytol 24:409-433.
97. Moffett JR, Namboodiri MA, et al. 1991. Immunohistochemical localization of N-acetylaspartate in rat brain. Neuroreport 2:131-134.
98. Moreno A, Ross BD, Bluml S. 2001. Direct determination of the N-acetyl-L-aspartate synthesis rate in the human brain by (13)C MRS and [1-(13)C]glucose infusion. J Neurochem 77: 347-350.
99. Neale JH, Bzdega T, Wroblewska B. 2000. N-acetylaspartylglutamate: The most abundant peptide neurotransmitter in the mammalian CNS. J Neurochem 75:443-452.
100. Nelson E. 1971. Nosology of the leukodystrophies: Ultrastructural contributions. Birth Defects Orig Artic Ser 7:113-116.
101. Parpura V, Haydon PG. 2000. Physiological astrocytic calcium levels stimulate glutamate release to modulate adjacent neurons. Proc Natl Acad Sci USA 97:8629-8634.
102. Patel TB, Clark JB. 1979. Synthesis of N-acetyl-L-aspartate by rat brain mitochondria and its involvement in mitochondrial/cytosolic carbon transport. Biochem J 184:539-546.
103. Pearce JM. 2004. Canavan's disease. J Neurol Neurosurg Psychiatry 75:1410.
104. Readhead C, Hood L. 1990. The dysmyelinating mouse mutations shiverer (shi) and myelin deficient (shimld). Behav Genet 20:213-234.
105. Rubin Y, LaPlaca MC, Smith DH, et al. 1995. The effect of N-acetylaspartate on the intracellular free calcium concentration in NTera2-neurons. Neurosci Lett 198:209-212.
106. Rudkin TM, Arnold DL. 1999. Proton magnetic resonance spectroscopy for the diagnosis and management of cerebral disorders. Arch Neurol 56:919-926.
107. Sacks O, Brown WJ, Aguilar MJ. 1965. Spongy degeneration of white matter: Canavan's sclerosis. Neurology 15:165-171.
108. Sener RN. 2003. Canavan disease: Diffusion magnetic resonance imaging findings. J Comput Assist Tomogr 27:30-33.
109. Simmons ML, Frondoza CG, Coyle JT. 1991. Immunocytochemical localization of N-acetylaspartate with monoclonal antibodies. Neuroscience 45:37-45.
110. Sorg BJ, Agrawal D, Agrawal HC. et al. 1986. Expression of myelin proteolipid protein and basic protein in normal and dysmyelinating mutant mice. J Neurochem 46:379-387.
111. Spillson AB, Russell JW. 2003. Metabotropic glutamate receptor regulation of neuronal cell death. Exp Neurol 184 (Suppl 1):S97-S105.
112. Staffen W, Zauner H, Mair A, et al. 2005. Magnetic resonance spectroscopy of memory and frontal brain region in early multiple sclerosis. J Neuropsychiatry Clin Neurosci 17:357-363.
113. Surendran S, Bamforth FJ, Chan A, et al. 2003a. Mild elevation of N-acetylaspartic acid and macrocephaly: Diagnostic problem. J Child Neurol 18:809-812.
114. Surendran S, Ezell EL, Quast MJ, et al. 2004. Aspartoacylase deficiency does not affect N-acetylaspartylglutamate level or glutamate carboxypeptidase II activity in the knockout mouse brain. Brain Res 1016:268-271.
115. Surendran S, Rady PL, Michals-Matalon K, et al. 2003b. Expression of glutamate transporter, GABRA6, serine proteinase inhibitor 2 and low levels of glutamate and GABA in the brain of knock-out mouse for Canavan disease. Brain Res Bull 61:427-435.
116. Tacke U, Olbrich H, Sass JO, et al. 2005. Possible genotype-phenotype correlations in children with mild clinical course of Canavan disease. Neuropediatrics 36:252-255.
117. Tallan HH. 1957. Studies on the distribution of N-acetyl-L-aspartic acid in brain. J Biol Chem 224:41-45.
118. Tallan HH, Moore S, Stein WH. 1956. N-acetyl-L-aspartic acid in brain. J Biol Chem 219: 257-264.
119. Toft PB, Geiss-Holtorff R, Rolland MO, et al. 1993. Magnetic resonance imaging in juvenile Canavan disease. Eur Disabil Rehabil 152:750-753.
120. Traeger EC, Rapin I. 1998. The clinical course of Canavan disease. Pediatr Neurol 18:207-212.
121. Trofatter JA, Dlouhy SR, DeMyer W, et al. 1989. Pelizaeus-Merzbacher disease: Tight linkage to proteolipid protein gene exon variant. Proc Natl Acad Sci USA 86:9427-9430.
122. Unga M, Goodman R. 1973. Spongy degeneration of the CNS (van Bogaert and Bertrand type; Canavan's disease). Human Pathol 4:331-346.
123. Urenjak J, Williams SR, Gadian DG, et al. 1992. Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro. J Neurochem 59:55-61.
124. Urenjak J, Williams SR, Gadian DG, et al. 1993. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 13:981-989.
125. van Bogaert L, Bertrand I. 1949. Sur une idiotie familiale avec degenerescense sponglieuse de neuraxe (note preliminaire). Acta Neurol Belg 49:572-587.
126. van Bogaert L, Bertrand I. 1967. Spongy Degeneration of the Brain in Israel. Amsterdam: North Holland.
127. van der Knaap MS. 2001. Magnetic resonance in childhood white-matter disorders. Dev Med Child Neurol 43:705-712.
128. Wang C, Wang CM, Clark KR, et al. 2003. Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain. Gene Ther 10:1528-1534.
129. Whiteman ML, Post MJ, Berger JR, et al. 1993. Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: Neuroimaging with clinical and pathologic correlation. Radiology 187:233-240.
130. Wroblewska B, Santi MR, Neale JH. 1998. N-acetylaspartylglutamate activates cyclic AMP-coupled metabotropic glutamate receptors in cerebellar astrocytes. Glia 24:172-179.
131. Wroblewska B, Wroblewski JT, Pshenichkin S, et al. 1997. N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J Neurochem 69:174-181.
132. Wroblewska B, Wroblewski JT, Saab OH, et al. 1993. N- acetylaspartylglutamate inhibits forskolin-stimulated cyclic AMP levels via a metabotropic glutamate receptor in cultured cerebellar granule cells. J Neurochem 61:943-948.
133. Yalcinkaya C, Benbi G, Salomons GS, et al. 2005. Atypical MRI findings in Canavan disease: A patient with a mild course. Neuropediatrics 36:336-339.